L3VLUP
ProSign in

DHR · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

DHRJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • DHR
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterDHRJNJ
Q3 202032 holders, $29.1bn30 holders, $26.2bn
Q4 202036 holders, $29.1bn32 holders, $26.6bn
Q1 202139 holders, $29.4bn31 holders, $25.3bn
Q2 202130 holders, $33.9bn37 holders, $25.6bn
Q3 202135 holders, $37.5bn40 holders, $24.1bn
Q4 202140 holders, $39.7bn33 holders, $25.2bn
Q1 202230 holders, $33.5bn35 holders, $28.2bn
Q2 202230 holders, $28.1bn33 holders, $26.9bn
Q3 202229 holders, $27.1bn36 holders, $25.4bn
Q4 202231 holders, $27.1bn35 holders, $27.6bn
Q1 202340 holders, $25.3bn42 holders, $24.5bn
Q2 202344 holders, $25.4bn38 holders, $25.0bn
Q3 202338 holders, $27.3bn37 holders, $18.9bn
Q4 202332 holders, $25.2bn31 holders, $19.0bn
Q1 202433 holders, $26.8bn32 holders, $19.7bn
Q2 202425 holders, $25.0bn35 holders, $20.4bn
Q3 202430 holders, $29.0bn28 holders, $22.3bn
Q4 202433 holders, $23.9bn37 holders, $20.4bn
Q1 202543 holders, $21.5bn32 holders, $20.5bn
Q2 202541 holders, $18.6bn31 holders, $18.4bn
Q3 202538 holders, $15.9bn32 holders, $23.7bn
Q4 202539 holders, $20.4bn29 holders, $27.8bn
Q1 202636 holders, $19.5bn34 holders, $35.6bn
Q2 202637 holders, $20.8bn33 holders, $39.1bn
DHR

Danaher Corp Del

Holders
39
Reported value
$20.4bn
Buyers
27
Sellers
23

Breadth +4 among 92 comparable managers.

IndustrialsHealthcare: biopharma and medtech · L3VLUPIndustrials and automation · L3VLUP
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 46 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only DHR (17)

Akre Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Citadel Advisors LLC, D1 Capital Partners LP, ExodusPoint Capital Management LP, Glenview Capital Management LLC, Harris Associates LP, Holocene Advisors LP, Moore Capital Management LP, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC, Steadfast Capital Management LP, Third Point LLC, Verition Fund Management LLC, Walleye Capital LLC, Winton Group Ltd

Only JNJ (7)

Acadian Asset Management LLC, Element Capital Management LLC, GAMCO Investors Inc, Hudson Bay Capital Management LP, Markel Group Inc, Marshall Wace LLP, Two Sigma Advisers LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →